Appleton Partners Inc. MA lifted its holdings in Edwards Lifesciences Corp (NYSE:EW) by 19.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 12,305 shares of the medical research company’s stock after purchasing an additional 1,990 shares during the period. Appleton Partners Inc. MA’s holdings in Edwards Lifesciences were worth $1,387,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. ETF Managers Group LLC purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $112,000. MPS Loria Financial Planners LLC purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $140,000. Dupont Capital Management Corp purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $142,000. Captrust Financial Advisors purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $149,000. Finally, Salem Investment Counselors Inc. lifted its position in shares of Edwards Lifesciences by 16.3% in the 2nd quarter. Salem Investment Counselors Inc. now owns 1,419 shares of the medical research company’s stock worth $168,000 after purchasing an additional 199 shares during the period. 81.36% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently weighed in on EW shares. Cowen set a $135.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Sunday, December 10th. BMO Capital Markets reaffirmed a “buy” rating and issued a $137.00 price target on shares of Edwards Lifesciences in a research report on Friday, December 8th. Canaccord Genuity reissued a “buy” rating and set a $137.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, November 29th. SunTrust Banks set a $124.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, Barclays decreased their target price on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 25th. Six analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Edwards Lifesciences presently has an average rating of “Buy” and a consensus target price of $129.57.
Edwards Lifesciences Corp (EW) opened at $120.83 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. Edwards Lifesciences Corp has a 52 week low of $86.55 and a 52 week high of $121.45. The stock has a market cap of $25,392.27, a P/E ratio of 35.13, a price-to-earnings-growth ratio of 1.92 and a beta of 0.51.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The company had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same quarter in the previous year, the company posted $0.68 EPS. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. equities research analysts expect that Edwards Lifesciences Corp will post 3.76 earnings per share for the current fiscal year.
Edwards Lifesciences announced that its board has approved a stock buyback plan on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.
In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction on Friday, December 28th. The shares were sold at an average price of $114.08, for a total transaction of $604,624.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Larry L. Wood sold 18,960 shares of the firm’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $108.54, for a total transaction of $2,057,918.40. The disclosure for this sale can be found here. Insiders have sold a total of 210,480 shares of company stock worth $23,056,527 in the last 90 days. 2.13% of the stock is currently owned by company insiders.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.